Johnson & Johnson stock advances as prostate drug combo enters Phase 3

Published on 11/12/2026 at 14:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock gained as early prostate-cancer results supported further testing of its dual-bispecific antibody regimen. Phase 3 is under way.

Prostate Cancer Program Advances

Johnson & Johnson reported preliminary Phase 1 results for a dual-bispecific antibody combination in advanced prostate cancer.
The regimen is being tested in the ongoing Phase 3 KLK2-comPAS study.
Early safety findings showed no Grade 3 or higher treatment-related adverse events at the recommended regimen.

Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson reported preliminary Phase 1 results on November 8, 2026, for a combination of the investigational bispecific antibodies pasritamig and JNJ-9401 in advanced prostate cancer. At the recommended regimen, 11 of 15 patients recorded prostate-specific antigen reductions of at least 50%, according to the StockTitan report, which reproduced the company release.

Seven of the 15 patients, or 47%, achieved PSA reductions of at least 90%. All seven remained on treatment for more than six months without disease progression, while four patients reached undetectable PSA levels. The findings were presented at the Society for Immunotherapy of Cancer 2026 annual meeting on November 7.

Small Study, Larger Test Ahead

The results come from an early analysis of heavily pretreated patients with metastatic castration-resistant prostate cancer. As of June 15, 2026, 144 patients had enrolled in the wider study, while the recommended-regimen analysis covered 15 patients who had received a median of four prior systemic therapies.

The recommended regimen combines JNJ-9401 at 200 milligrams with pasritamig at 300 milligrams every six weeks, following two weekly pasritamig step-up doses. Johnson & Johnson said the combination is being evaluated in the ongoing Phase 3 KLK2-comPAS study, which is testing whether adding JNJ-9401 to pasritamig can improve outcomes.

The early safety profile was favorable, but the small patient group limits the conclusions investors can draw. No Grade 3 or higher treatment-related adverse events, dose-limiting toxicities, treatment-related discontinuations or treatment-related deaths were reported at the recommended regimen. Cytokine release syndrome occurred in three patients, with all cases classified as Grade 1 temporary fever.

Pipeline Signal Meets Market Focus

Johnson & Johnson stock traded at EUR 255.20 on Lang & Schwarz at 14:12 CET on Thursday, November 12, 2026, 1.94% above the Xetra close of Wednesday, November 11. The comparison uses the prior Xetra session because the current session had not yet closed.

For investors, the prostate-cancer program offers a potential growth avenue in Innovative Medicine, but Phase 3 results and regulatory progress remain the decisive milestones. The company also faces the normal development risks of an investigational therapy, including whether early PSA responses translate into durable clinical benefit in a larger population.

The broader Euro Stoxx 50 market provides the regional backdrop for healthcare-sector trading.

More news and analyses on Johnson & Johnson stock.